Singapore, London, New York, May 18, 2020. Holmusk, a leading data science and health technology company, today announced a US$21.5 million funding round. The round was led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals.

Holmusk is building the world’s largest Real-World Evidence (RWE) platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. This is made possible by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that care providers, health care payers and patients can use to make fully informed care and treatment decisions, and better integrate care for people with both behavioral and chronic health needs. These capabilities can also aid pharma companies with R&D and commercialization of new drugs.

In 2016, Holmusk acquired MindLinc, an Electronic Health Record (EHR) system focused on behavioral health, from Duke University School of Medicine. This enabled the company to leverage longitudinal data from many mental health institutions across US, stretching over 20 years.

Founded in 2015, Holmusk is headquartered in Singapore with offices in New York City, London and Shanghai. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum and is part of the Innovations in Healthcare’s 2020 Innovator Cohort. The new funding round allows Holmusk to expand its US operations in New York City, and enables investment in its proprietary technology to harness and analyze real-world data to accelerate drug development and data-driven medicine.

Dr. Vijay Barathan from Optum Ventures (OV) and Charles Boorady from Health Catalyst Capital (HCC) will be joining the Board of Directors.

"Our team is encouraged by Holmusk’s evidence-based approach to improving care for people suffering from behavioral health disorders, and we look forward to working closely with the Holmusk team to support the next phase of growth" said Dr. Vijay Barathan of Optum Ventures.

Charles Boorady of Health Catalyst Capital said "by redefining the EHR from a repository of data to a clinical decision support tool with connectivity to digital therapeutics, Holmusk is uniquely positioned to improve patient care while reducing administrative burden and supporting the research and development of new care models and therapies."

"In situations like today, the need for Real-World Evidence is more pronounced than ever," said Nawal Roy, Holmusk’s Founder & CEO. "We are fortunate to bring on partners like Optum Ventures and Health Catalyst Capital who understand the importance and are excited to join us in our mission to drive evidence-based care."

• The World Economic Forum has announced its selection of the 56 most promising Technology Pioneers of 2019 who are shaping industries from agriculture and cleantech to modern policing and many more.
• Companies were selected for their potential to “transform their industries” and “improve society for years to come,” Fulvia Montresor of the World Economic Forum said.
• Holmusk, which is building the world’s largest Real-World Evidence (RWE) platform in mental health, was selected for its contributions in the field of neuroscience.
• The full list of recognized Technology Pioneers can be viewed here.

Singapore, July 1, 2019 - Holmusk, a Singapore-headquartered data science and digital therapeutics company with a global presence, was selected among hundreds of candidates as one of the World Economic Forum’s "Technology Pioneers". Holmusk, dedicated to establishing objective evidence as a core utility to the treatment of mental health, uses its proprietary technology to analyze real-world data across mental health and other chronic metabolic diseases to accelerate drug development and inform personalized care.

The World Economic Forum’s Technology Pioneers are early to growth-stage companies from around the world that are involved in the design, development and deployment of new technologies and innovations, and are poised to have a significant impact on business and society.

This year’s Tech Pioneers are emerging innovators from a diverse set of industries. These firms are shaping the future by advancing technologies such as AI, IoT, robotics, blockchain, biotechnology and many more. The focus areas of this year’s Tech Pioneers include: agtech, smart cities, cleantech, supply chain, manufacturing, cybersecurity, autonomous vehicles and drones. The diversity of these companies extends to their leadership as well, as 25% of 2019 Tech Pioneers are female led. The firms also come from many different regions beyond the United States and Silicon Valley. In fact, this year’s class of 56 firms represent every continent except Antarctica. The full list of technology pioneers can be found here.

Following its selection as Technology Pioneer, Founder & CEO Nawal Roy of Holmusk will be participating in the World Economic Forum Annual Meeting of the New Champions. This meeting, also dubbed "Summer Davos" will be held in Dalian, China, July 1-3. Many Pioneers will also attend the Annual Meeting in Davos, in January 2020, and continue to contribute to Forum initiatives over the next two years.

"We’re excited to welcome Holmusk to this year’s innovative class of technology pioneers," says Fulvia Montresor, Head of Technology Pioneers at the World Economic Forum. "Holmusk and its fellow pioneers are leaders in using novel technologies to transform their industries. We see great potential for these next generation companies to shape solutions to global challenges and improve society for years to come."

"We are privileged to be acknowledged as pioneer by the World Economic Forum", said Holmusk’s Nawal Roy. "It is a confirmation that our work in mental health is transforming the sector, and that data-driven medicine that leverages analytic and digital tools can address this unmet need. Regardless the region of the world, people are underserved when it comes to mental health. We aim to illuminate the global challenge and drive leapfrog-change in the provision of care, research and treatments."

The Technology Pioneers were selected by a selection committee of more than 59 academics, entrepreneurs, venture capitalists and corporate executives. The committee based its decisions on criteria including innovation, potential impact and leadership. Past recipients include Airbnb, Google, Kickstarter, Mozilla, Palantir Technologies, Spotify, TransferWise, Twitter and Wikimedia.

All info on this year’s Technology Pioneers can be found here.

More information on past winners can be found here.

About Holmusk: Holmusk is a data science and digital therapeutics company dedicated to addressing how the world confronts mental health. With a mission to build the world’s largest Real-World Evidence (RWE) platform for mental health, we are establishing data as a core utility to the treatment of mental health and other chronic metabolic diseases through evidence-based decision making. Holmusk is Singapore-headquartered, with offices in New York, Shanghai, London, Malaysia and North Carolina.

About World Economic Forum: The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business and other leaders of society to shape global, regional and industry agendas. (www.weforum.org).

Singapore - Beijing, June 19, 2019 - Holmusk has signed a Memorandum of Understanding (MoU) with Janssen (China) Research & Development Center (Janssen), a Division of Johnson & Johnson (China) Investment Ltd., to explore the development of a digital mental health strategy in China. The MoU brings together Janssen’s 60-plus years of experience developing treatments to improve mental health and its China neuroscience portfolio with Holmusk’s digital mental health platform and therapeutics design expertise to develop integrated solutions to help people living with depression and other mental health disorders.

More than 54 million people in China (4.2% of the population) suffer from depression. Proper diagnosis and treatment for depression is rare, especially in underserved regions, with less than 2 out of 10 patients seeking medical help or taking medications. Stigma regarding mental health remains high, preventing many patients from seeking care, and China has only 1.7 psychiatrists for every 100,000 people. While depression costs China USD 7.8 billion a year in lost work days, medical expenses and funeral expenses, there is a lack of available, credible data on both prevalence and treatment.

As described in the MoU, Holmusk and Janssen propose to focus on generating insights from real-world data on depression and other mental health disorders to develop novel, scalable solutions to address the increasing burden of disease in the People’s Republic of China. The parties would also identify areas of unmet need that a digital platform can enhance, and define the supporting, prioritized functionality based on the Janssen Neuroscience portfolio in China. Holmusk’s digital therapeutics and deep analytics will be used to develop and implement a competitive, comprehensive solution for mental health in China, with an initial focus on depression.

Holmusk will work with Janssen to develop a strategy that applies Holmusk’s digital therapeutics capabilities and deep mental health analytics expertise to leverage big data and real-world evidence for a broad spectrum of mental health challenges. The combination of Holmusk’s mental health platform and Janssen’s expertise and network will be used to inform future, targeted management of wellness-oriented consumers, as well as mental health patients.

"We are excited to work with Janssen, an organization trusted by patients and customers, to develop much-needed solutions for people battling mental health diseases," said Nawal Roy, Founder and CEO of Holmusk. "In Janssen, we have a partner that is dedicated to transforming how mental health is managed in China. We have confidence that we can establish data as a core utility to the treatment of mental health and provide the capacity for leapfrog-change in the provision of care and research into new treatments."

Holmusk is a data science and digital health company building the world’s largest real-world evidence platform for neuroscience. Holmusk’s MoU with Janssen is in line with its efforts to share subject matter expertise with leading innovators to improve mental health in Mainland China.

For media enquiries, please contact:

Holmusk

Paul Feldhausen

paul.feldhausen@holmusk.com

+65 6250 4233

Switzerland – Singapore, March 25, 2019 - The Department of Internal Medicine at University Hospital of Zurich and Curo-Health / Holmusk, a digital health and data analytics company, today announced the start of a research collaboration to advance the clinical management of patients with multiple diseases and depression.

Ancillary depression is increasingly prevalent and increases health care costs. In hospitalized patients with multiple diseases, an ancillary depression reduces therapeutic success, worsens clinical outcomes and prolongs the length of hospital stay. Currently, the impact of ancillary depression in multimorbid hospitalized patients is not well established. Being able to identify and address depression effectively during hospitalization has the potential to improve the clinical management of patients, improve outcomes, and to reduce the length of hospital stays.

The Department of Internal Medicine of the University Hospital of Zurich will apply a range of advanced analytic methods developed by Holmusk to investigate the impact of ancillary depression in multimorbid patients. The analytic solutions are for four years on the market, mainly in Asia and the US. Holmusk approach combines artificial intelligence, system biology and pharmacological models to generate new insights. The use of this technology is expected to allow the researchers at the department of Internal Medicine at University Hospital of Zurich to better understand complex disease interactions and design personalized therapies for their complex patients with ancillary depression.

“Our data show that a cluster of patients with ancillary depression is independently associated with a longer length of stay in hospital and more frequent readmissions,” says Professor Eduoard Battegay, head of Department of Internal Medicine at University Hospital of Zurich. “Advanced clinical analytics can open ways for us to offer personalized and effective medicine to our patients that is evidence based, and may reduce health care costs and improve quality of life of patients.”

Stefan Suter, founder and CEO of Curo-Health said, “In today’s complex world and sophisticated technologies applied, the best results are produced when rallying different skill sets towards a common goal. This research collaboration between industry and academic partners is a great example of this; one we should make happen more often.”

“Appropriate healthcare is more than treating the main condition - it’s about understanding and treating individuals holistically. With this collaboration, we will better understand the effects of ancillary depression and bring informed, personalized care to patients with multiple diseases.” Said Nawal Roy, Founder and CEO of Holmusk.

For media enquiries, please contact:
Stefan Suter, CEO, Curo-Health, +41 79 402 2241
Paul Feldhausen, Business Practice Manager, Holmusk, +65 9170 2619

About University Hospital of Zurich

The University Hospital Zurich (USZ) is open to all patients every day and provides fundamental medical care and cutting-edge medicine in a central location in Zurich. We use our superior academic knowledge to treat a wide range of health issues, taking a personal touch and utilizing highly specialized and up-to-date research. We research the latest treatment methods and apply them according to strict scientific criteria. We are the sole provider of many therapies in Switzerland. Patients with complex and multiple health problems travel from all over the country and abroad to be treated here. The percentage of patients with complex diseases is particularly high at the USZ.

About Holmusk

Holmusk, a Singapore based, is building the world's largest real-world evidence platform for neuroscience. We leverage our technology to work with real world data across chronic diseases. The company’s goal is to transform healthcare by data driven medicine. Holmusk’s proprietary modeling platform leverages scientific research and digital healthcare data to inform predictive algorithms and provide actionable insights for personalized medicine. Its innovative, scalable and cost-effective digital behavior change programs are designed to nudge people towards better health. For more information, visit: holmusk.com

About Curo-Health

Curo-Health headquarter is in Basel-area, Switzerland and is the license holder for Holmusk products in Europe. Curo-Health is executing projects to increase efficiency in health care. We focus on delivering patient relevant outcomes based on evidence and data at lower costs. Our goal is to transform todays health system into a value-based care system. Our activities span across Europe and Asia. For more information, visit: www.curo-health.com

Singapore, January 22, 2019 - Caregiver Asia Pte Ltd, an online aggregator of trusted on-demand health and caregiving services, and Holmusk, a digital health and data science company, partner to wage war against diabetes – a disease that affects one in nine Singaporeans.

Supplementing the CaregiverPlus Programme – a customised home care management service by CaregiverAsia – Holmusk’s GlycoLeap app will enable the CaregiverAsia user community to prevent or control diabetes through a mobile dietician coach. "Careseekers who are suffering from diabetes or are concerned about keeping the disease at bay will be recommended to subscribe to the GlycoLeap app by our Nurse Consultants," said Kumari Rai, CaregiverAsia’s Nurse Manager. Along with a comprehensive care plan provided by CaregiverPlus, a healthier weight and lifestyle can be achieved in three to six months.

GlycoLeap will also be made readily available on CaregiverAsia’s newly launched E-store at https://estore.caregiverasia.com, allowing customers to subscribe for the service through an integrated marketplace.

Said Ms Yeo Wan Ling, CEO of CaregiverAsia, “This partnership allows CaregiverAsia to take our home care and care management services to the next level. With the GlycoLeap app, our customised care plans for diabetes will be augmented by Holmusk’s crew of dietitians who are available in real-time for advice and guidance. Innovative startups working together by leveraging on their unique strengths are an excellent way of providing ground-breaking solutions to everyday problems. We look forward to more exciting partnerships like the one we have with Holmusk."

Nawal Roy, CEO of Holmusk had this to share, “We’re really happy to partner with CaregiverAsia to provide their members direct access to GlycoLeap, a digital programme which empowers people with chronic diseases like diabetes to manage their health and stay healthy. In today’s rapidly aging society, innovative solutions like CaregiverAsia’s on demand home care services and Holmusk’s GlycoLeap make it extremely simple and convenient for people to access the professional care they need, whenever they need it."

About Caregiver Asia Pte Ltd

CaregiverAsia is an online aggregator of health and caregiving services. Through its award winning platform, CaregiverAsia has created an online marketplace leveraging on a shared economy of Careseekers and Caregivers. Careseekers can access on-time, trusted and transparent home care services; whilst freelance Caregivers and healthcare professionals can practice independently with full control of their schedules and terms of services. CaregiverAsia also specializes in healthcare recruitment and the placement of healthcare professionals and locums into leading healthcare institutions. For more information, please visit https://www.caregiverasia.com/

CaregiverAsia is part of The Caregiver Group which is headquartered in Singapore. The Caregiver Group is a global online aggregator of health and caregiving services for businesses and individuals, covering both the insured and the self-funded. By motivating and empowering freelance professionals, The Group transforms the way care is delivered to people and communities. The Group has a growing international presence in Malaysia and the United States. For more information, please visit http://www.thecaregivergroup.com/

About Holmusk

Holmusk is a digital health and data science company, on a mission to build the largest Real World Evidence (RWE) platform in neuroscience and for chronic diseases. The company’s goal is to transform healthcare by data driven medicine. Holmusk’s proprietary modelling platform leverages scientific research and digital healthcare data to inform predictive algorithms and provide actionable insights for personalised medicine. Its innovative, scalable and cost-effective digital behaviour change programs are designed to nudge people towards better health. For more information, please visit http://www.holmusk.com

CaregiverAsia media contact:

Joel Tam

Director, Marketing

Tel: (65) 6258 6683 / (65) 8118 9281

Email: joeltam@caregiverasia.com

Holmusk media contact:

Paul Feldhausen

Business Practice Manager

Tel: (65) 9170 2619

Email: paul.feldhausen@holmusk.com

New York, January 7, 2019 - Holmusk became a resident company of Johnson & Johnson Innovation, JLABS (JLABS @ NYC), a premier life science incubator program. With its residency, Holmusk is excited to interact with other resident companies and looks forward to expanding its US footprint and deepening its relationship with partners and stakeholders within the pharma/life science hub of the US east coast.

Holmusk’s team at JLABS @ NYC will focus on building the world’s largest real-world evidence (RWE) platform for behavioral health. This platform will incorporate the latest evidence from clinical trials and real-world data, brining insights to the point of care. Additionally, the platform will serve as a stepping stone to drive innovation among pharma companies to serve patients with unmet needs and allow quicker access to new drugs.

Holmusk is proud to be a part of JLABS @ NYC, which provides an ideal stage to interact with the life science ecosystem. “Being part of JLABS is like being part of a world class network of entrepreneurs and thought leaders – we are excited to join the conversation," said Holmusk’s Founder and CEO Nawal Roy.

JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

About Holmusk:

Holmusk is a digital health and data science company, on a mission to build the largest Real World Evidence (RWE) platform in neuroscience and for chronic diseases. The company’s goal is to transform healthcare by data driven medicine. Holmusk’s proprietary modeling platform leverages scientific research and digital healthcare data to inform predictive algorithms and provide actionable insights for personalized medicine. Its innovative, scalable and cost-effective digital behavior change programs are designed to nudge people towards better health. For more information, visit: holmusk.com

Singapore, September 25, 2018 - Holmusk, a Singapore-headquartered digital health and data analytics company with a global presence, today announced closing of USD$9.75 million in Pre-Series A financing. The financing round included funding from Heritas Venture Fund as well as participation from new and existing investors. The funds allow Holmusk to expand its footprint in USA and Europe.

Holmusk leverages technology and data science to accelerate research and improve outcomes for people with chronic diseases and behavioral health disorders. Partnering with Pharma and healthcare providers, Holmusk informs predictive algorithms and provide actionable insights for personalized medicine through its proprietary modelling platform. Alongside this, it has an innovative digital health platform for patient engagement.

“Holmusk’s focus on promoting healthy lifestyles and addressing chronic disease management made this an exciting opportunity to be a part of," said Chik Wai Chiew, CEO of Heritas Capital Management which oversees Heritas Venture Fund. “Its approach of combining deep analytics with clinical research and real-world data is promising and we are pleased to see the company on track to build upon the successes of GlycoLeap and SuperLeap and develop next generation versions in 2019."

Holmusk is also expanding its assets in behavioral health. Having acquired MindLinc, a behavioral health EHR, it now holds one of the largest behavioral health databases in the world. Combining system dynamics with deep learning neural networks and quantitative systems pharmacology, Holmusk is developing MindLinc 2.0 which will include predictive disease models based on longitudinal patient data.

Based out of Singapore, Holmusk has offices in the US, UK and Malaysia. “Holmusk’s technology platforms for behavioral health and chronic diseases have global application and we are excited about our expansion into USA and Europe. We look forward to sustaining the momentum as we grow our client base around the world" said Kenneth Ng, investor and Holmusk board chairman and co-founder/CIO for NTAsset.

“I’m excited that we are entering this next stage of growth. This financing reflects the trust our investors have in us and gives us a healthy financial runway, which allows us to focus on executing and growing aggressively in our core segments of chronic disease management and behavioral health." Nawal Roy, Founder and CEO explained. “The world is faced with unprecedented health challenges and we’re thrilled to play our part in addressing them."

About Holmusk

Holmusk is a healthcare company on a mission to leverage the power of human relationships, technology and data to prevent, manage and reverse chronic disease and behavioural health issues. Our proprietary modelling platform leverages scientific research and digital healthcare data to inform predictive algorithms and provide actionable insights for personalized medicine. We build innovative, scalable and cost-effective digital behaviour change programs designed to nudge people towards better health. For more information visit: holmusk.com

Basel, Switzerland, April 3, 2017 - Today, Ascensia Diabetes Care has revealed the six entries that will progress to the finalist stage of the Ascensia Diabetes Challenge, a global innovation competition that is seeking digital solutions to support type 2 diabetes management. The six finalists were selected from 116 submissions that were received and were chosen by a panel consisting of external experts and members of the Ascensia Medical, R&D and Commercial teams. The selected companies will now present their solutions at the finalist event in April to determine the winner, which will subsequently be announced at the American Diabetes Association 78th Scientific Sessions in June.

“We’ve received entries from entrepreneurs and start-ups around the world who are at the forefront of healthcare innovation. We have been delighted by the quality and variety of the submissions we have received, which offer digital solutions that could revolutionize a number of aspects of type 2 diabetes management,” stated Michael Kloss, CEO of Ascensia Diabetes Care. “We are now looking forward to the finalist event and hearing more about these truly innovative ideas.”

With type 2 diabetes currently accounting for around 90% of the estimated 425 million people with diabetes globally (IDF Diabetes Atlas, 8th Edition (2017), new innovative ways to manage this condition are urgently required to meet the substantial and growing burden to the individuals and our healthcare systems. Through the challenge, Ascensia is looking to support the companies and entrepreneurs developing the next leap forward in digital solutions that could facilitate better type 2 diabetes management and improve the lives of people with diabetes.

This global challenge attracted a high calibre of submissions from across North America, Asia and Europe, representing some of the latest technology and innovative thinking entering the field of type 2 diabetes management. After much deliberation by the judging panel, the following finalists were selected:

Foodient by Whisk: An artificial intelligence powered Digital Dietician that connects people to the world’s leading grocery retailers. It is being developed to help type 2 diabetes patients easily find food they love and is nutritionally tailored, so that they can make sustainable behaviour change. https://whisk.com/

GlycoLeap by Holmusk: A digital health program that is a simpler way to lose weight and lower A1c. It combines expert human coaching with mobile technology to empower people with type 2 diabetes live a healthier life. GlycoLeap is powered by a scalable, engaging and effective technology platform for data-driven, personalised health coaching. https://www.glycoleap.com/

QStream: A team-based mobile game developed at Harvard Medical School that can prompt meaningful behavior change in people with type 2 diabetes. QStream is proven to generate significant and sustained improvements in blood glucose control among patients who use it. https://qstreamhealthcare.com

My Diabetes Coach by Macadamian: A voice first diabetes management platform that uses Amazon’s Alexa to help those with type 2 diabetes better manage their care. The data captured through an integrated wearable device, a mobile phone, and dialogue with the patient provides a personal and empathetic virtual coaching experience that is enabled through artificial intelligence. http://www.macadamian.com/

Path Feel by Walk with Path: An active feedback insole that provides vibrational, or haptic, feedback to the user during walking. This can aid people with diabetic neuropathy in being able to feel the ground and achieve balance. Path Feel is a connected digital solution and integrates data from the insole, which can be used to personalise and enhance care. https://www.walkwithpath.com/

xbird: Medical artificial intelligence software that analyzes micro-movements, collected by smartphones and wearables worn by people with diabetes, and cross references them with historical blood glucose data in order to predict and detect potential hypo- and hyperglycaemic events. The solution creates actionable insights for both doctors and patients. http://www.xbird.io/

The six finalists will all receive a €10,000 cash prize to support the further development of their ideas. Following the finalist event, prizes for the winners and runners-up will be awarded from the total prize fund of €200,000, with the opportunity to partner with Ascensia Diabetes Care.

For further information on the Ascensia Diabetes Challenge, the judges and judging criteria, please visit: https://ascensiadiabeteschallenge.com/.

Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

© 2018 Ascensia Diabetes Care. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.

Singapore, October, 2, 2017 - The University of Oxford and Holmusk, a digital health and data analytic company, signed a data transfer agreement to collaborate in investigating metabolism in type 2 diabetes.

The collaboration will establish a working relationship between The University of Oxford and Holmusk to obtain and construct models based on metabolic and metabolomic data in type 2 diabetic hearts. The objective is to produce metabolic pathway models, to predict changes in metabolism in the diabetic heart. This will not only provide insights on the mechanisms that drive abnormal cardiac metabolism but it will also enable us to identify new therapeutic targets for type 2 diabetes.

Dr. Lisa Heather will be leading the research for this collaboration from the University of Oxford while Dr. Latt Mansor, Director, Business Development and Joydeep Sarkar, Director of Data Science will be leading the initiative from Holmusk. Dr. Latt Mansor, who was Dr. Heather’s first DPhil graduate, is excited to work with his alma mater and be a part of the team to expand current understanding of diabetic metabolism using academic research data and data analytics. His passion has always been to bring together academic research and industry expertise.

Nawal Roy, founder and CEO of Holmusk, stated that there should be more collaborations of this nature between industry and academia to optimise the valuable skill sets that both parties can bring to the table. He hopes that the combined international talent pool from both University of Oxford and Holmusk can accelerate knowledge generation as well as create insights for innovation in the healthcare ecosystem.

About the Heather Group, DPAG, University of Oxford

Dr. Lisa Heather is a University Research Lecturer at the Department of Physiology, Anatomy and Genetics and Isobel Laing Fellow at Oriel College. Her group investigates the role abnormal cardiac metabolism plays in the development of heart failure and diastolic dysfunction.

About Holmusk

Holmusk is a global digital health and data analytics company, focused on solving complex problems in healthcare for chronic diseases. We build innovative, scalable and cost-effective digital behaviour change programs that combine cutting-edge clinical research, technology and design to nudge people towards sustainable changes for better health. We develop powerful predictive algorithms that offer actionable insights for personalised care and population health management. We are based in Singapore, Malaysia and USA.For more information on Holmusk, visit www.holmusk.com

Singapore, April 6, 2017 - Holmusk, a global digital health and data analytics company — has embarked on a three-year partnership with National Heart Centre Singapore (NHCS) to improve care for heart failure and coronary artery disease using big data analytics to build better predictive models that can be validated for use in the treatment and prevention of cardiovascular disease in Singapore.

Supported by the Singapore Economic Development Board (EDB), Holmusk will collaborate with NHCS to analyse aggregated data from the Singapore Cardiac Longitudinal Outcomes Database (SingCLOUD) to drive insights and build effective tools for clinical decision support.

“Our aim in this project is to track clinical outcomes and design targeted intervention strategies that improve care in patients with heart failure or coronary artery disease", said Associate Professor Yeo Khung Keong, a Senior Consultant at NHCS.

“Innovations in healthcare is happening at a rapid pace globally. Precision medicine is the future of healthcare and big data analytics will play a significant role to improve clinical outcomes as well as operational and financial outcomes" said Nawal Roy, CEO and Founder of Holmusk. “Our focus is to bring cutting edge analytic practices that facilitate early detection and early intervention to engage patients before they become chronic. This initiative could turn into a nationwide effort to optimize efficiency and improve clinical outcomes for cardiovascular patients in Singapore, while providing a gold standard of reference for the APAC region. It is a great privilege to work with researchers and clinicians at NHCS. Most importantly, we are very proud to have the esteemed backing of EDB.“

“Healthcare is a growing and evolving sector where value creation is driven by evidence-backed innovation, with a clear focus on better patient outcomes," said Ms. Ho Weng Si, Director of the Biomedical Sciences division at EDB. “This partnership is a promising example of local private and public sector collaboration to create data-driven healthcare solutions which will improve healthcare in Singapore and the region."

This partnership is a 3 year-long project that will run through to 2019.

About Holmusk

Holmusk is a global digital health and data analytics company, focused on solving complex problems in healthcare for chronic diseases. We build innovative, scalable and cost-effective digital behaviour change programs that combine cutting-edge clinical research, technology and design to nudge people towards sustainable changes for better health. We develop powerful predictive algorithms that offer actionable insights for personalised care and population health management. We are based in Singapore, Malaysia and USA.For more information on Holmusk, visit www.holmusk.com

Singapore, March 27, 2017 - The National University of Singapore (NUS) and Holmusk, a digital health and data analytics company, signed a Memorandum of Understanding (MOU) recently to explore collaborations for improving healthcare delivery in the region.

Under this MOU, the Biomedical Institute for Global Health Research and Technology (BIGHEART) at NUS and Holmusk will establish a working relationship on several topics related to healthcare IT and medical device development. These include personal informatics and intervention through healthcare applications, such as mobile food logging, diabetes management and mental health. Another area to be explored is the analysis of personal health data from surveys, smart phones and wearables, electronic medical records and other clinical data.

“There are many critical healthcare challenges faced by both developed and developing countries today” said Professor Luke P. Lee, founding director of BIGHEART at NUS.” This collaboration will allow us to take our interdisciplinary research further, by collaborating with Holmusk on apps, digital technology and predictive analytics. Together, we believe we can move closer towards overcoming some of the technical barriers that prevent good healthcare in the region.

“BIGHEART at NUS is at the forefront of basic and translational healthcare research. We are excited to lend our digital health and data analytics experience and capabilities to these projects, in order to commercialise and bring pioneering research to the region in a practical and sustainable manner” said Nawal Roy, CEO and Founder of Holmusk.

About National University of Singapore (NUS)

A leading global university centred in Asia, the National University of Singapore (NUS) is Singapore’s flagship university, which offers a global approach to education and research, with a focus on Asian perspectives and expertise.

NUS has 17 faculties and schools across three campuses. Its transformative education includes a broad-based curriculum underscored by multi-disciplinary courses and cross-faculty enrichment. Over 38,000 students from 100 countries enrich the community with their diverse social and cultural perspectives.

NUS has three Research Centres of Excellence (RCE) and 30 university-level research institutes and centres. It is also a partner in Singapore’s fifth RCE. The University has established many research partnerships and joint laboratories with academic institutions, industry leaders and government agencies. Research activities are strategic and robust, and NUS is well-known for its research strengths in engineering, life sciences and biomedicine, social sciences and natural sciences. The University also strives to create a supportive and innovative environment to promote creative enterprise within its community.

For more information on NUS, visit www.nus.edu.sg.

About BIGHEART

BIGHEART was established in 2016 at the National University of Singapore (NUS). BIGHEART conducts interdisciplinary research to address the technical barriers preventing distributed global healthcare solutions. Our mission is to transform research and education and shape the future of healthcare by the creative convergence of life sciences, physical sciences, engineering, medicine, and the arts for innovative healthcare technologies.

For more information on BIGHEART, visit BIGHEART.nus.edu.sg

Holmusk is a global digital health and data analytics company, focused on solving complex problems in healthcare for chronic diseases. We build innovative, scalable and cost-effective digital behaviour change programs that combine cutting-edge clinical research, technology and design to nudge people towards sustainable changes for better health. We develop powerful predictive algorithms that offer actionable insights for personalised care and population health management. We are based in Singapore, Malaysia and USA.

For more information on Holmusk, visit www.holmusk.com

Singapore, November 22, 2016 - Holmusk, a global digital health and data analytics company headquartered in Singapore, will present GlycoLeap – a digital diabetes management program – at the World Innovation Summit for Health (WISH) ‘Innovation Showcases’.

The Innovation Showcases Gallery at WISH will feature some of the world’s most exciting healthcare innovations, ranging from practical devices to business models and design-based solutions.

GlycoLeap uses concepts from behavioural science to drive positive health outcomes for people with diabetes. Through small and sustainable lifestyle changes, users can achieve moderate weight loss and improve glucose control (as measured by HbA1c) within 6-months of the GlycoLeap program.

“This is a great opportunity for us to show our novel approach to improving care and outcomes for people with chronic disease,” said Nawal Roy, CEO and Founder of Holmusk. “It has been great working with the WISH team in the run up to the event and we are looking forward to meeting potential collaborators and partners through the WISH network.”

The event will be held from 29th to 30th November, 2016 in Doha, Qatar.

About Holmusk

Holmusk is a global digital health and data analytics company, focused on solving complex problems in healthcare for chronic diseases. We build innovative, scalable and cost-effective digital behaviour change programs that combine cutting-edge clinical research, technology and design to nudge people towards sustainable changes for better health. We develop powerful predictive algorithms that offer actionable insights for personalised care and population health management. We are based in Singapore and USA. For more information on Holmusk, visit www.holmusk.com

About GlycoLeap

GlycoLeap is a smart coach for type 2 diabetes that you can access anytime, anywhere. It provides you with the support you need to reach your health goals in less time, such as better glucose control, a healthier weight, and keeping up with exercise and diet changes. We combine human expert coaching with smart technology – all from your smartphone.For more information on GlycoLeap, visit www.glycoleap.com

About WISH

WISH is a global initiative of Qatar Foundation for Education, Science and Community Development. The 2016 summit will focus on seven specific challenges: Healthy Populations, Precision Medicine, Economic Benefits of Investing in Health, Cardiovascular Disease, Accountable Care, Autism and Behavioural Insights. WISH will also report on its ongoing impact locally and globally on issues previously highlighted at the conference, such as diabetes and patient safety.For more information on WISH, visit www.wish-qatar.org

Singapore, October 3,2016 - GlycoLeap, developed by Holmusk, combines expert human coaching with mobile technology to empower people with Type 2 Diabetes to live a healthier life.

A new smart coach supports people living with type 2 diabetes to make positive changes in their lives to prevent long-term complications. This solution combines human expertise and mobile technology to nudge patients towards healthier habits and a better quality of life.

Holmusk, a digital health and data analytics company, launched its flagship product, a smart coach for type 2 diabetes, in August 2016. Called GlycoLeap, it delivers human coaching via a mobile app and integrates connected health tracking tools. The app is available for iOS and Android.

“GlycoLeap is transformative for people with diabetes, especially in the way it brings diabetes care out of the clinics and hospitals and into people’s every day lives,” said Nawal Roy, CEO and Founder of Holmusk. “We want to contribute towards revolutionising the healthcare experience for people living with chronic disease.”

Diabetes affects more than 415 million people worldwide – a number that continues to rise each year. A 2015 study by the International Diabetes Federation (IDF) found that Singapore has the second-highest proportion of people with diabetes among all developed nations – more than 10 percent of people aged 20 to 79. Three out of every 10 patients with diabetes develop the condition before age 40.

GlycoLeap uses concepts from behavioural science to drive positive health outcomes for people with diabetes. Through small and sustainable lifestyle changes, users can achieve moderate weight loss and improve glucose control (as measured by HbA1c) within 6-months of the GlycoLeap program.

As part of the program, users take photographs of their meals with Glyco app. A coaching team of qualified dietitians rate the meals and provide daily feedback and support. Users are also provided smart devices, including a wireless scale, glucometer and fitness band to track weight, blood glucose and physical activity. This gives the coaching team a 360-degree view of each user’s behaviour, allowing them to provide the right feedback and support at the right time.

“After using GlycoLeap for 6 months, my HbA1c was reduced from 8.7 to 6.2 percent,” said Singapore user Wen Shi. “The feedback provided by the dietitians on food rating has helped me realise what types of food are good at controlling my glucose.”

Healthcare costs associated with diabetes continue to be a major concern worldwide. Diabetes-related complications are a major cause of hospitalisation. According to a 2016 article in the BMC Public Health journal, Singapore’s healthcare spending for diabetes rose above $1 billion in 2010 and is expected to soar beyond $2.5 billion by 2050.

The high costs of diabetes – both for the individual and the healthcare system – and the personal nature of diabetes management presents an opportunity for technologies that can provide scalable and engaging solutions for better diabetes management. GlycoLeap has the potential to fill this need.

Plans are currently in the works to develop tailored programs for people with prediabetes – as well as other chronic diseases, such as high blood pressure and high cholesterol – in the next 6 months.

GlycoLeap is currently available in Singapore and expected to become available in the United States, Malaysia, and Hong Kong by early 2017.

For more information on GlycoLeap, please visit https://glycoleap.com/

About GlycoLeap

GlycoLeap is a smart coach for type 2 diabetes that you can access anytime, anywhere. It provides you with the support you need to reach your health goals in less time, such as better glucose control, a healthier weight, and keeping up with exercise and diet changes. We combine human expert coaching with smart technology – all from your smartphone. We believe that everyone has the power to transform their life in a sustainable way, if given the right support. Diabetes does not have to be complicated or difficult. And we’ve done this with GlycoLeap – beautifully designed, simple to use and convenient.For more information on GlycoLeap, visit www.glycoleap.com

About Holmusk

Holmusk is a global digital health and data analytics company, focused on solving complex problems in healthcare for chronic diseases. We build innovative, scalable and cost-effective digital behaviour change programs that combine cutting-edge clinical research, technology and design to nudge people towards sustainable changes for better health. We develop powerful predictive algorithms that offer actionable insights for personalised care and population health management. We are based in Singapore and USA. For more information on Holmusk, visit www.holmusk.com

North Carolina, USA, November 1, 2015 - Duke University School of Medicine (DUSoM) and Holmusk, a global digital health platform, recently announced that Holmusk will acquire rights in Duke’s Mindlinc software system. Holmusk will become the distributor of MindLinc and will provide further development and support for that software. With the shift from fee-for-service to fee-for-value, healthcare has to deliver better patient outcomes. Big population health care data companies like Holmusk can deliver solutions using advanced analytics that span many diseases.

Holmusk’s further development and distribution of the MindLinc software seeks to improve care management for mental health and other behavioral issues by leveraging data from electronic medical records, connected medical devices, claims and clinical research data. The ultimate goal is to develop a new generation of clinical and operational tools to facilitate better insights, feedback, recommendations and decision support. Holmusk expects these tools will enable physicians and patients to make timely, evidence-based and personalized decisions about health and disease management.

DUSoM has been a pioneer in behavioral health research and innovation. MindLinc offers a comprehensive behavioral health records managementsolution developed by experts at Duke. Thanks to Duke’s pioneering role in behavioral health research and treatment, MindLinc is the industry leader in behavioral functionality and decision support. Its solutions offer seamless integration of clinical psychiatric care at all levels; regulatory management, research, and evidence based quality improvement. Customers employ the MindLinc Rules engine to establish and enforce clinical evidence based practices, treatment guidelines. Customers also can use Mindlinc’s clinical outcomes data and MindLinc’s Global database to help improve care and demonstrate outcomes for Pay-for-Performance and ACO management. Clinicians and researchers use MindLinc data to secure grants, conduct research. The addition of MindLinc clients to Holmusk accelerates the growth of a comprehensive ecosystem of tools, data, and services to provide disease management decision support for health care providers. MindLinc clients will now have access to Holmusk’s digital platforms for chronic disease management, development, support, and services to help them deliver quality care and maximize operational efficiencies.

“We are pleased to collaborate with Holmusk to innovate further through novel data science and technology," says Dr. Barry Myers, DUSoM. “We believe this collaboration has the potential to help us develop decision making tools that could allow hospitals and doctors to determine the necessity, extent and timing of specific treatments with greater precision."

“Data science holds immense potential for healthcare sector. Global trends are clear that data science is integral part of the future of healthcare – across large healthcare enterprises as well as for specialized clinical specialties," says Nawal Roy, CEO and Founder of Holmusk. “With this relationship, we are confident that we can help to influence the way we manage behavioral health and chronic diseases. We are deeply honored for the opportunity to work with MindLinc’s clients and DuSoM’s clinical and research community."

About Mindlinc

MindLinc’s EMR is a comprehensive electronic behavioral health records management system developed by experts at Duke University School of Medicine. This full stack EMR-EPM system may be SaaS-hosted, hybrid-hosted, or client-server based. MindLinc seamlessly integrates clinical psychiatric care and Practice Management at all levels; regulatory management, research, and evidence based quality improvement. Our intuitive technologies and expertise provide customers the best flexible solutions to meet the needs of mental health centers, psychiatric hospitals, substance abuse clinics and other behavioral healthcare professionals. MindLinc is an ONC compliant system and suited for practices of all sizes. For more information on Mindlinc, visit www.mindlinc.com

About Holmusk

Holmusk is a pioneering big data and digital health company focused on addressing the growing epidemic of chronic diseases. Holmusk develops innovative, scalable and cost-effective digital disease management programs, combining cutting-edge clinical research, technology and design to help patients improve their health. Holmusk also integrates diverse and abundant health data to create powerful predictive algorithms to offer actionable insights for personalized care and population health management. In short, Holmusk’s mission is to improve health outcomes.For more information on Holmusk, visit www.holmusk.com

Singapore, August 3, 2015 - Duke-NUS Graduate Medical School Singapore (Duke-NUS) and Holmusk, a global tele-health platform, have recently announced a collaboration to further the potential of big data in healthcare. Big data refers to very large, unstructured and diverse datasets that cannot be managed using conventional methods. In healthcare, big data and analytics allow us to discover patterns that would not be found otherwise, and make predictions about disease. This has the potential to improve care and lower costs.

The collaboration will focus on addressing ways to improve care management for diabetes and mental health. The aim is to leverage information collected from personal health records, medical and fitness devices, as well as more traditional sources of health data such as medical records, claims data and clinical research. The result will be a new generation of tools that offer better insights, real-time feedback and recommendations. These will enable physicians and patients to make timely, evidence-based and personalised decisions about health and disease management.

“We are excited to be contributing to the healthcare IT space in Singapore,” said Associate Professor David Epstein, Director of Duke-NUS’ Centre for Technology and Development. “With the decision-making tools that will come from this collaboration, it will be possible for hospitals and doctors to adopt a more patient-centric approach to determining the necessity, extent and timing for particular treatments.”

“We’re looking forward to helping develop and evaluate tools that can be applied in the hospital setting to cost-effectively improved delivery of patient services,” said Professor Eric Finkelstein from the Health Services and Systems Research Programme at Duke-NUS. Professor Finkelstein will be overseeing the collaboration with Holmusk on the Duke-NUS campus. His research focuses on health technology assessment and the use of incentives to influence health behaviours.

“From banking to retail, many sectors have already embraced big data,” said Nawal Roy, CEO and founder of Holmusk. “We’re still in the early days of the big data revolution in healthcare. With this collaboration, we can help to transform the way we manage health. By putting powerful and accurate decision support tools into the hands of patients and doctors, we can make the system more efficient, cost-effective and data-driven. Ultimately, we want to improve patient outcomes.”

###

Source: Duke-NUS Medical School